• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

优化从包涵体中回收 HIV-1 蛋白酶(C-SA)的程序。

Optimized Procedure for Recovering HIV-1 Protease (C-SA) from Inclusion Bodies.

机构信息

Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa.

School of Life Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa.

出版信息

Protein J. 2019 Feb;38(1):30-36. doi: 10.1007/s10930-018-9805-7.

DOI:10.1007/s10930-018-9805-7
PMID:30666487
Abstract

HIV-1 is an infectious virus that causes acquired immunodeficiency syndrome (AIDS) and it is one of the major causes of deaths worldwide. The production of HIV-1 protease (PR) on a large scale has been a problem for scientists due to its cytotoxicity, low yield, insolubility, and low activity. HIV-1 C-SA protease has been cloned, expressed, and purified previously, however, with low recovery (0.25 mg/L). Herein we report an optimal expression and solubilisation procedure to recover active HIV-1 C-SA protease enzyme from inclusion bodies. The HIV protease was expressed in seven different vectors (pET11b, pET15b, pET28a pET32a, pET39b, pET41b and pGEX 6P-1). The highest expression was achieved when the vector pET32a (Trx tag) was employed. A total of 19.5 mg of fusion protein was refolded of which 5.5 mg of active protease was obtained after cleavage. The free protease had a high specific activity of 2.81 µmoles/min/mg. Interestingly the Trx-fusion protein also showed activity closer (1.24 µmoles/min/mg) to that of the free protease suggesting that the pET32a vector (Trx tag) expressed in BL21(DE3) pLysS provides a more efficient way to obtain HIV-1 protease.

摘要

HIV-1 是一种传染性病毒,可导致获得性免疫缺陷综合征(AIDS),是全球主要死亡原因之一。由于 HIV-1 蛋白酶(PR)具有细胞毒性、产量低、不溶性和低活性,因此大规模生产一直是科学家面临的问题。此前,HIV-1 C-SA 蛋白酶已被克隆、表达和纯化,但回收率低(0.25mg/L)。在此,我们报告了一种从包涵体中回收有活性的 HIV-1 C-SA 蛋白酶的最佳表达和溶解程序。HIV 蛋白酶在七种不同载体(pET11b、pET15b、pET28a、pET32a、pET39b、pET41b 和 pGEX6P-1)中进行表达。当使用载体 pET32a(Trx 标签)时,表达量最高。共折叠了 19.5mg 的融合蛋白,经切割后获得了 5.5mg 的活性蛋白酶。游离蛋白酶具有 2.81 µmoles/min/mg 的高比活。有趣的是,Trx 融合蛋白的活性也接近游离蛋白酶(1.24 µmoles/min/mg),这表明 BL21(DE3)pLysS 中表达的 pET32a 载体(Trx 标签)提供了一种更有效的获得 HIV-1 蛋白酶的方法。

相似文献

1
Optimized Procedure for Recovering HIV-1 Protease (C-SA) from Inclusion Bodies.优化从包涵体中回收 HIV-1 蛋白酶(C-SA)的程序。
Protein J. 2019 Feb;38(1):30-36. doi: 10.1007/s10930-018-9805-7.
2
Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies.从包涵体中纯化和鉴定天然存在的HIV-1(南非C亚型)蛋白酶突变体。
Protein Expr Purif. 2016 Jun;122:90-6. doi: 10.1016/j.pep.2016.02.013. Epub 2016 Feb 23.
3
An efficient procedure for the expression and purification of HIV-1 protease from inclusion bodies.一种从包涵体中表达和纯化HIV-1蛋白酶的高效方法。
Protein Expr Purif. 2015 Dec;116:59-65. doi: 10.1016/j.pep.2015.07.011. Epub 2015 Jul 29.
4
Two-Step Preparation of Highly Pure, Soluble HIV Protease from Inclusion Bodies Recombinantly Expressed in Escherichia coli.从在大肠杆菌中重组表达的包涵体中两步制备高纯度、可溶性HIV蛋白酶
Curr Protoc Protein Sci. 2020 Jun;100(1):e106. doi: 10.1002/cpps.106.
5
Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies.从大肠杆菌包涵体中大规模纯化和重折叠HIV-1蛋白酶。
J Protein Chem. 1993 Jun;12(3):323-7. doi: 10.1007/BF01028194.
6
Optimizing HIV-1 protease production in Escherichia coli as fusion protein.优化 HIV-1 蛋白酶在大肠杆菌中的融合蛋白表达。
Microb Cell Fact. 2011 Jun 30;10:53. doi: 10.1186/1475-2859-10-53.
7
Large-scale production of HIV-1 protease from Escherichia coli using selective extraction and membrane fractionation.
Protein Expr Purif. 1995 Aug;6(4):512-8. doi: 10.1006/prep.1995.1068.
8
Expression and purification of active form of HIV-1 protease from E.coli.从大肠杆菌中表达并纯化HIV-1蛋白酶的活性形式。
Biochem Mol Biol Int. 1995 Apr;35(4):899-912.
9
High-level synthesis of recombinant HIV-1 protease and the recovery of active enzyme from inclusion bodies.
Gene. 1990 Mar 15;87(2):243-8. doi: 10.1016/0378-1119(90)90308-e.
10
Use of chemical cleavage to release active HIV-1 proteinase from a fusion protein produced in the form of insoluble inclusion bodies.
Biochem Soc Trans. 1992 May;20(2):162S. doi: 10.1042/bst020162s.

引用本文的文献

1
Robotics for enzyme technology: innovations and technological perspectives.机器人技术在酶技术中的应用:创新与技术展望。
Appl Microbiol Biotechnol. 2021 May;105(10):4089-4097. doi: 10.1007/s00253-021-11302-1. Epub 2021 May 10.

本文引用的文献

1
I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.南非C亚型(C-SA)HIV-1蛋白酶中的I36T↑T突变显著改变蛋白酶与药物的相互作用。
Biol Chem. 2017 Sep 26;398(10):1109-1117. doi: 10.1515/hsz-2017-0107.
2
Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies.从包涵体中纯化和鉴定天然存在的HIV-1(南非C亚型)蛋白酶突变体。
Protein Expr Purif. 2016 Jun;122:90-6. doi: 10.1016/j.pep.2016.02.013. Epub 2016 Feb 23.
3
Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.
HIV-1感染与衰老:运动功能、认知和注意力——与帕金森病的比较
Neuropsychol Rev. 2015 Dec;25(4):424-38. doi: 10.1007/s11065-015-9305-x. Epub 2015 Nov 17.
4
An efficient procedure for the expression and purification of HIV-1 protease from inclusion bodies.一种从包涵体中表达和纯化HIV-1蛋白酶的高效方法。
Protein Expr Purif. 2015 Dec;116:59-65. doi: 10.1016/j.pep.2015.07.011. Epub 2015 Jul 29.
5
Latest approaches for efficient protein production in drug discovery.药物研发中高效蛋白质生产的最新方法。
Expert Opin Drug Discov. 2014 Oct;9(10):1189-204. doi: 10.1517/17460441.2014.941801. Epub 2014 Jul 21.
6
Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system.用于大肠杆菌中蛋白质溶解性、纯化及免疫原性的融合标签:新型Fh8系统
Front Microbiol. 2014 Feb 19;5:63. doi: 10.3389/fmicb.2014.00063. eCollection 2014.
7
HIV-1 Protease: Structural Perspectives on Drug Resistance.HIV-1 蛋白酶:耐药性的结构视角。
Viruses. 2009 Dec;1(3):1110-36. doi: 10.3390/v1031110. Epub 2009 Dec 3.
8
Optimizing HIV-1 protease production in Escherichia coli as fusion protein.优化 HIV-1 蛋白酶在大肠杆菌中的融合蛋白表达。
Microb Cell Fact. 2011 Jun 30;10:53. doi: 10.1186/1475-2859-10-53.
9
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.HIV-1蛋白酶抑制剂:上市10年后的最新进展。从抗逆转录病毒药物到基于天冬氨酸蛋白酶抑制剂的抗真菌、抗菌和抗肿瘤药物。
Curr Med Chem. 2007;14(26):2734-48. doi: 10.2174/092986707782360141.
10
HIV drug development: the next 25 years.艾滋病病毒药物研发:未来25年
Nat Rev Drug Discov. 2007 Dec;6(12):959-66. doi: 10.1038/nrd2336.